Press Releases

View: All Categories General Releases Financial Releases Year: All Years 2010 2009 2008 2007 2006 2005 2004 All Releases Oncothyreon announces second quarter 2010 financial results conference call Jul 26, 2010 9.1 KB   SEATTLE, WA, July 26, 2010 /PRNewswire via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq: ONTY) will conduct a conference call to discuss its second quarter 2010 financial results on Thursday, August 5, 2010 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the call by telephone, please dial (877) 280-7291 (United States) or... Read more Oncothyreon secures $20 million committed equity financing facility Jul 7, 2010 11.4 KB   SEATTLE, WA, July 7, 2010 /PRNewswire via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq: ONTY) today announced that it has secured a committed equity financing facility under which it may sell up to $20 million of its shares of common stock to Small Cap Biotech Value, Ltd. (the "investor") over a 24-month period. Oncothyreon is not obligated to ... Read more Oncothyreon announces that Merck Serono is resuming the Stimuvax clinical program in lung cancer Jun 17, 2010 13.9 KB   SEATTLE, WA, June 17, 2010 /PRNewswire via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq: ONTY) today announced that Merck Serono, a division of Merck KGaA of Darmstadt, Germany, and its U.S. affiliate, EMD Serono, Inc., are resuming the worldwide clinical development program for Stimuvax(R) (BLP25 liposomal vaccine) in non-small cell lung cance... Read more Oncothyreon announces presentation of Phase 1 data for PX-866 and PX-478 at American Society of Clinical Oncology Annual Meeting Jun 7, 2010 16.1 KB   SEATTLE, WA, June 7, 2010 /PRNewswire via COMTEX News Network/ -- DESCRIBES PHASE 2 DEVELOPMENT PLANS FOR PX-866 Oncothyreon Inc. (Nasdaq: ONTY) (the "Company") announced that results from Phase 1 clinical trials of the Company's small molecule product candidates PX-866, an irreversible inhibitor of PI-3 kinase, and PX-478, an inhibitor of HIF-1 a... Read more Oncothyreon announces presentations at upcoming investor conferences in June Jun 3, 2010 9.2 KB   SEATTLE, WA, June 3, 2010 /PRNewswire via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June. Presentations include: - The Noble Financial Sixth Annual Equity Conference on Tuesday, Ju... Read more Oncothyreon announces presentations at American Society Of Clinical Oncology (ASCO) Annual Meeting May 21, 2010 9.9 KB   SEATTLE, May 21, 2010 /PRNewswire via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq: ONTY) today announced that data highlighting the Company's two small molecule programs will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 4 through 8, 2010 in Chicago. Clinical data regarding Oncothyreon's produ... Read more Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference May 12, 2010 9.0 KB   SEATTLE, May 12, 2010 /PRNewswire via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Rodman & Renshaw Annual Global Investment Conference taking place in London on May 16-18, 2010. Dr. Kirkman will present at 10:15 a.m. British Summer Tim... Read more Oncothyreon announces compliance with Nasdaq listing requirements May 10, 2010 9.3 KB   SEATTLE, May 10, 2010 /PRNewswire via COMTEX News Network/ -- Oncothyreon Inc. (NASDAQ: ONTY) today announced that it received written confirmation on May 7, 2010 from the Nasdaq Listing Qualifications Staff that the company has demonstrated compliance with Nasdaq Marketplace Rule 5250(c)(1) for continued listing of the company's securities on The ... Read more Oncothyreon reports first quarter 2010 financial results May 6, 2010 14.1 KB   SEATTLE, WA, May 6, 2010 /PRNewswire via COMTEX News Network/ -- Oncothyreon Inc. (NASDAQ: ONTY) (the "Company") today reported a net loss of $0.8 million or $0.03 per basic and diluted share for the quarter ended March 31, 2010, compared with a net loss of $2.5 million or $0.13 per basic and diluted share for the comparable period in 2009. The dec... Read more Oncothyreon reports full year and fourth quarter 2009 financial results May 6, 2010 19.7 KB   SEATTLE, May 6, 2010 /PRNewswire via COMTEX News Network/ -- Concludes restatement of prior financial results Company to hold conference call at 4:30 EDT today Oncothyreon Inc. (NASDAQ: ONTY) (the "Company") today reported financial results for the year and quarter ending December 31, 2009. The Company also announced today that it filed its Annua... Read more Oncothyreon to conduct conference call for year end 2009 and first quarter 2010 financial results on Thursday, May 6, 2010 May 5, 2010 9.2 KB   SEATTLE, May 5, 2010 /PRNewswire via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq: ONTY) announced today it will report its 2009 year end and first quarter 2010 financial results on Thursday, May 6, 2010 after the close of U.S. financial markets, followed by a conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate i... Read more Oncothyreon working to meet NASDAQ requirements Apr 22, 2010 11.0 KB   SEATTLE, April 22, 2010 /PRNewswire via COMTEX News Network/ -- COMPANY RECEIVES NOTICE FROM NASDAQ REGARDING 2009 FORM 10-K Oncothyreon Inc. (NASDAQ: ONTY) announced today that it has received a staff deficiency notice from the NASDAQ Listing Qualifications Staff stating that it is not currently in compliance with NASDAQ Marketplace Rule 5250(c)(... Read more Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono Mar 23, 2010 14.0 KB   SEATTLE, March 23, 2010 /PRNewswire via COMTEX News Network/ -- ONCOTHYREON TO HOLD TELECONFERENCE AT 5:00 PM EDT Oncothyreon Inc. (Nasdaq: ONTY) today announced that Merck Serono, a division of Merck KGaA of Darmstadt, Germany, and its U.S. affiliate, EMD Serono, Inc., have temporarily suspended the worldwide clinical development program for Stim... Read more Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement Mar 12, 2010 17.3 KB   SEATTLE, WA, March 12, 2010 /PRNewswire via COMTEX News Network/ -- COMPANY TO RESTATE EITHER DISCLOSURE OR ACCOUNTING TREATMENT Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will restate its 2008 financial statements contained in its Annual Report on Form 10-K for the year ended December 31, 2008, and its Quarterly Reports on Form 10-Q ... Read more Oncothyreon announces termination of arrangement agreement Mar 9, 2010 9.4 KB   SEATTLE, WA, March 8, 2010 /PRNewswire via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq: ONTY) today announced that Gamehost Income Fund ("Gamehost") has determined that certain proposed changes to the Income Tax Act (Canada) announced on March 4, 2010 by the Canadian Federal Minister of Finance will adversely affect the benefit to Gamehost of ... Read more Oncothyreon announces presentations at upcoming investor conferences Mar 8, 2010 9.3 KB   SEATTLE, March 8, 2010 /PRNewswire via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq: ONTY) announced today that management will participate in two upcoming investor conferences. Robert Kirkman, M.D., President and Chief Executive Officer, will present at the 22nd Annual ROTH OC Growth Stock Conference in Dana Point, CA, at 4:30 p.m. Pacific Ti... Read more Oncothyreon announces sale of Oncothyreon Canada Feb 18, 2010 11.9 KB   SEATTLE, Feb 18, 2010 /PRNewswire via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq: ONTY) today announced that it has entered into an arrangement agreement (the "Arrangement") pursuant to which it will sell its interests in Oncothyreon Canada Inc., an indirect wholly owned subsidiary, and 0811769 B.C. ULC, an indirect wholly owned subsidiary an... Read more Oncothyreon to present at BIO CEO & Investor Conference Feb 2, 2010 9.2 KB   SEATTLE, WA, Feb 02, 2010 /PRNewswire via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the 12th Annual BIO CEO & Investor Conference taking place Feb. 8-9, 2010 in New York. Dr. Kirkman will present at 10 a.m. Eastern Time on Tuesday, Feb. ... Read more Oncothyreon announces initiation of Phase 3 trial of Stimuvax in Asian patients with NSCLC Dec 10, 2009 12.2 KB   SEATTLE, Dec. 10, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) today announced that Merck KGaA of Darmstadt, Germany, has initiated a Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC). The trial, named INSPIRE (Stimuvax trial In Asian NSCLC P... Read more Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover Nov 16, 2009 13.4 KB   SEATTLE, Nov. 16, 2009 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (the "Company") today announced that the Company's product candidate PX-866, a PI-3 kinase inhibitor, has been selected by Windhover Information, Inc., as one of the Top 10 most promising oncology projects in development that is available for partner... Read more Showing 1-20 of 178 Page: 1 2 3 ... 9  Next 20 = add release to Briefcase return to top ^